| Literature DB >> 2994227 |
R S Chang, V J Lotti, R L Monaghan, J Birnbaum, E O Stapley, M A Goetz, G Albers-Schönberg, A A Patchett, J M Liesch, O D Hensens.
Abstract
A new, competitive, nonpeptide cholecystokinin (CCK) antagonist, asperlicin, was isolated from the fungus Aspergillus alliaceus. The compound has 300 to 400 times the affinity for pancreatic, ileal, and gallbladder CCK receptors than proglumide, a standard agent of this class. Moreover, asperlicin is highly selective for peripheral CCK receptors relative to brain CCK and gastrin receptors. Since asperlicin also exhibits long-lasting CCK antagonist activity in vivo, it should provide a valuable tool for investigating the physiological and pharmacological actions of CCK.Entities:
Mesh：
Substances：
Year: 1985 PMID： 2994227 DOI： 10.1126/science.2994227
Source DB: PubMed Journal: Science ISSN： 0036-8075 Impact factor: 47.728